SPC changes
Accessing SPCs
The summaries of product characteristics and patient
information leaflets for medicines licensed in the UK are available online |
Actonel Once a Week
Treatment of osteoporosis in men at high risk of fractures has been added
as an indication in the summary of product characteristics for Actonel
Once a Week (risedronate sodium; Procter and Gamble). The dose for this
indication is 35mg once a week.
Avastin
First-line treatment of patients with unresectable advanced, metastatic
or recurrent non-small cell lung cancer (other than predominantly squamous
cell histology) has been added as an indication in the summary of product
characteristics for Avastin (bevacizumab; Roche).
For this indication,
Avastin is administered in addition to platinum-based chemotherapy
for up to six cycles of treatment, followed by Avastin as a single
agent until disease progression. The recommended dose is 7.5mg/kg
or 15mg/kg of body weight once every three weeks as an intravenous infusion. Diovan
A recommendation that serum potassium should be monitored in renally
impaired or elderly patients taking potassium supplements has been
added to the summary of product characteristics for Diovan (valsartan;
Novartis). In addition, the SPC also states: “The safety and
efficacy of Diovan have not been established in children and adolescents
(below the age of 18 years)”.
Further information about use in
pregnancy and information about reports of overdose have also been
added to the SPC. Lescol
A warning about isolated cases of myopathy in patients with fluvastatin
and colchicine has been added to the summaries of product characteristics
for Lescol (fluvastatin; Novartis) and Lescol XL (fluvastatin). In
addition, pancreatitis has been added to the SPCs as a very rare undesirable
effect.
Prexige
Prexige (lumiracoxib; Novartis) is now contraindicated for patients who
have any current hepatic disease, previous drug-induced significant
elevations of transaminases (over three times the upper limit of the
normal range [ULN]), or liver transaminases >1.5 x ULN at baseline
or >3 x ULN during treatment, and for patients who are taking other
medicines associated with clinically significant hepatotoxicity.
Liver
function tests (LFTs) should be performed before starting treatment
and once a month when treatment is for longer than a month, and the
tests should be repeated after seven days if transamines are above
2 x ULN. In addition, patients reporting any systemic illness while
taking lumiracoxib should undergo LFTs.
The summary of product characteristics
also now states that liver damage has been reported following exposure
to Prexige, that patients should be advised to remain vigilant
for any symptoms compatible with hepatic injury during treatment (such
as anorexia, nausea, vomiting, abdominal pain, fatigue, dark urine,
jaundice, pruritus).
Patients should stop Prexige if any such symptoms
occur and should seek medical advice urgently. Patients should
be
reminded of normal limits of safe alcohol consumption while taking
lumiracoxib and that excessive alcohol consumption could aggravate
any drug-related
liver reaction.
Back to Top
|